New: Instantly spot drawdowns, dips, insider moves, and breakout themes across Maps and Screener.

ALTERITY THERAPEUTICS LIMITED

Contributing Author

Recent Articles by ALTERITY THERAPEUTICS LIMITED

Jan-30	Alterity Therapeutics: Appendix 4C - Q2 FY26 Quarterly Cash Flow Report & Corporate Update ATHE GlobeNewswire
Jan-21	Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026 ATHE GlobeNewswire
Nov-12	Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference ATHE GlobeNewswire
Nov-10	Alterity Therapeutics Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSA at the 36th International Symposium on the Autonomic Nervous System ATHE GlobeNewswire
Oct-31	Alterity Therapeutics: Appendix 4C - Q1 FY26 Quarterly Cash Flow Report ATHE GlobeNewswire
Oct-09	Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson's Disease and Movement Disorders ATHE GlobeNewswire
Oct-02	Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson's Disease and Movement Disorders ATHE GlobeNewswire
Sep-15	Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting ATHE GlobeNewswire
Sep-08	Alterity Therapeutics Raises A$20.0 million in Strategic Placement ATHE GlobeNewswire
Sep-02	Alterity Therapeutics to Present at the Biotech Showcase ATHE GlobeNewswire
Jul-30	Appendix 4C - Q4 FY25 Quarterly Cash Flow Report ATHE GlobeNewswire
Jul-28	Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy ATHE GlobeNewswire
Jul-24	Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study ATHE GlobeNewswire
Jun-23	Alterity Therapeutics to Provide Corporate Update in Fireside Chat ATHE GlobeNewswire
May-12	Alterity Therapeutics Prominently Featured at the International MSA Congress ATHE GlobeNewswire
May-07	Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress ATHE GlobeNewswire
May-05	Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy ATHE GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.